The features and prognostic impact of extracranial metastases in patients with epidermal growth factor receptor-mutant lung adenocarcinoma

Jianping Bi, Guang Han, Xueyan Wei, Guoliang Pi, Yong Zhang, Ying Li, Mingwei Wang, Desheng Hu, Weining Zhen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims: We have previously demonstrated that brain metastases were more common among patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. However, the association of EGFR mutation and extracranial metastases (ECM) remains inconclusive. In this study, we explored the potential association between EGFR mutation and the risk of ECM. Patients and Methods: Between March 2007 and December 2014, 234 patients were analyzed for the potential association between EGFR mutation and ECM. Statistical Analysis Used: Multivariate Cox regression analysis. Results: There were no associations between the EGFR mutation and metastases in different organs, except for bone. The frequency of EGFR mutation was statistically higher for patients with bone metastases (BMs) at the initial diagnosis (P = 0.039) and at the last follow-up (P = 0.018) as compared to those with wild-type EGFR. In multivariate logistic regression analysis, EGFR mutation significantly increased the risk of BM at the initial diagnosis (P = 0.036). Among those patients without BM at initial diagnosis, 1- and 2-year accumulative rates of subsequent BM were significantly higher in patients with EGFR-mutant disease (P = 0.026). EGFR mutation was an independent risk factor for subsequent BM (P < 0.05). In addition, patients with finial BM and EGFR-mutant disease had longer median survival as compared to those with wild-type disease (P = 0.020). Conclusions: Only BM in patients with ECM was significantly correlated with EGFR mutation during their disease course. EGFR mutation was an independent predictive and prognostic factor for developing BM, which was also a positive predictive factor for overall survival of patients who developed BM.

Original languageEnglish (US)
Pages (from-to)799-806
Number of pages8
JournalJournal of Cancer Research and Therapeutics
Volume14
Issue number4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Epidermal Growth Factor Receptor
Neoplasm Metastasis
Bone and Bones
Mutation
Adenocarcinoma of lung
Regression Analysis
Survival
Multivariate Analysis
Logistic Models

Keywords

  • Bone metastasis
  • epidermal growth factor receptor
  • extracranial metastasis
  • lung adenocarcinoma
  • mutation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

The features and prognostic impact of extracranial metastases in patients with epidermal growth factor receptor-mutant lung adenocarcinoma. / Bi, Jianping; Han, Guang; Wei, Xueyan; Pi, Guoliang; Zhang, Yong; Li, Ying; Wang, Mingwei; Hu, Desheng; Zhen, Weining.

In: Journal of Cancer Research and Therapeutics, Vol. 14, No. 4, 01.01.2018, p. 799-806.

Research output: Contribution to journalArticle

Bi, Jianping ; Han, Guang ; Wei, Xueyan ; Pi, Guoliang ; Zhang, Yong ; Li, Ying ; Wang, Mingwei ; Hu, Desheng ; Zhen, Weining. / The features and prognostic impact of extracranial metastases in patients with epidermal growth factor receptor-mutant lung adenocarcinoma. In: Journal of Cancer Research and Therapeutics. 2018 ; Vol. 14, No. 4. pp. 799-806.
@article{c74dc9b28ff246618e5488330972f98c,
title = "The features and prognostic impact of extracranial metastases in patients with epidermal growth factor receptor-mutant lung adenocarcinoma",
abstract = "Aims: We have previously demonstrated that brain metastases were more common among patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. However, the association of EGFR mutation and extracranial metastases (ECM) remains inconclusive. In this study, we explored the potential association between EGFR mutation and the risk of ECM. Patients and Methods: Between March 2007 and December 2014, 234 patients were analyzed for the potential association between EGFR mutation and ECM. Statistical Analysis Used: Multivariate Cox regression analysis. Results: There were no associations between the EGFR mutation and metastases in different organs, except for bone. The frequency of EGFR mutation was statistically higher for patients with bone metastases (BMs) at the initial diagnosis (P = 0.039) and at the last follow-up (P = 0.018) as compared to those with wild-type EGFR. In multivariate logistic regression analysis, EGFR mutation significantly increased the risk of BM at the initial diagnosis (P = 0.036). Among those patients without BM at initial diagnosis, 1- and 2-year accumulative rates of subsequent BM were significantly higher in patients with EGFR-mutant disease (P = 0.026). EGFR mutation was an independent risk factor for subsequent BM (P < 0.05). In addition, patients with finial BM and EGFR-mutant disease had longer median survival as compared to those with wild-type disease (P = 0.020). Conclusions: Only BM in patients with ECM was significantly correlated with EGFR mutation during their disease course. EGFR mutation was an independent predictive and prognostic factor for developing BM, which was also a positive predictive factor for overall survival of patients who developed BM.",
keywords = "Bone metastasis, epidermal growth factor receptor, extracranial metastasis, lung adenocarcinoma, mutation",
author = "Jianping Bi and Guang Han and Xueyan Wei and Guoliang Pi and Yong Zhang and Ying Li and Mingwei Wang and Desheng Hu and Weining Zhen",
year = "2018",
month = "1",
day = "1",
doi = "10.4103/jcrt.JCRT_824_17",
language = "English (US)",
volume = "14",
pages = "799--806",
journal = "Journal of Cancer Research and Therapeutics",
issn = "0973-1482",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - The features and prognostic impact of extracranial metastases in patients with epidermal growth factor receptor-mutant lung adenocarcinoma

AU - Bi, Jianping

AU - Han, Guang

AU - Wei, Xueyan

AU - Pi, Guoliang

AU - Zhang, Yong

AU - Li, Ying

AU - Wang, Mingwei

AU - Hu, Desheng

AU - Zhen, Weining

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aims: We have previously demonstrated that brain metastases were more common among patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. However, the association of EGFR mutation and extracranial metastases (ECM) remains inconclusive. In this study, we explored the potential association between EGFR mutation and the risk of ECM. Patients and Methods: Between March 2007 and December 2014, 234 patients were analyzed for the potential association between EGFR mutation and ECM. Statistical Analysis Used: Multivariate Cox regression analysis. Results: There were no associations between the EGFR mutation and metastases in different organs, except for bone. The frequency of EGFR mutation was statistically higher for patients with bone metastases (BMs) at the initial diagnosis (P = 0.039) and at the last follow-up (P = 0.018) as compared to those with wild-type EGFR. In multivariate logistic regression analysis, EGFR mutation significantly increased the risk of BM at the initial diagnosis (P = 0.036). Among those patients without BM at initial diagnosis, 1- and 2-year accumulative rates of subsequent BM were significantly higher in patients with EGFR-mutant disease (P = 0.026). EGFR mutation was an independent risk factor for subsequent BM (P < 0.05). In addition, patients with finial BM and EGFR-mutant disease had longer median survival as compared to those with wild-type disease (P = 0.020). Conclusions: Only BM in patients with ECM was significantly correlated with EGFR mutation during their disease course. EGFR mutation was an independent predictive and prognostic factor for developing BM, which was also a positive predictive factor for overall survival of patients who developed BM.

AB - Aims: We have previously demonstrated that brain metastases were more common among patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. However, the association of EGFR mutation and extracranial metastases (ECM) remains inconclusive. In this study, we explored the potential association between EGFR mutation and the risk of ECM. Patients and Methods: Between March 2007 and December 2014, 234 patients were analyzed for the potential association between EGFR mutation and ECM. Statistical Analysis Used: Multivariate Cox regression analysis. Results: There were no associations between the EGFR mutation and metastases in different organs, except for bone. The frequency of EGFR mutation was statistically higher for patients with bone metastases (BMs) at the initial diagnosis (P = 0.039) and at the last follow-up (P = 0.018) as compared to those with wild-type EGFR. In multivariate logistic regression analysis, EGFR mutation significantly increased the risk of BM at the initial diagnosis (P = 0.036). Among those patients without BM at initial diagnosis, 1- and 2-year accumulative rates of subsequent BM were significantly higher in patients with EGFR-mutant disease (P = 0.026). EGFR mutation was an independent risk factor for subsequent BM (P < 0.05). In addition, patients with finial BM and EGFR-mutant disease had longer median survival as compared to those with wild-type disease (P = 0.020). Conclusions: Only BM in patients with ECM was significantly correlated with EGFR mutation during their disease course. EGFR mutation was an independent predictive and prognostic factor for developing BM, which was also a positive predictive factor for overall survival of patients who developed BM.

KW - Bone metastasis

KW - epidermal growth factor receptor

KW - extracranial metastasis

KW - lung adenocarcinoma

KW - mutation

UR - http://www.scopus.com/inward/record.url?scp=85053374537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053374537&partnerID=8YFLogxK

U2 - 10.4103/jcrt.JCRT_824_17

DO - 10.4103/jcrt.JCRT_824_17

M3 - Article

C2 - 29970656

AN - SCOPUS:85053374537

VL - 14

SP - 799

EP - 806

JO - Journal of Cancer Research and Therapeutics

JF - Journal of Cancer Research and Therapeutics

SN - 0973-1482

IS - 4

ER -